Complement C1q (C1q Complement)
A subcomponent of complement C1, composed of six copies of three polypeptide chains (A, B, and C), each encoded by a separate gene (C1QA; C1QB; C1QC). This complex is arranged in nine subunits (six disulfide-linked dimers of A and B, and three disulfide-linked homodimers of C). C1q has binding sites for antibodies (the heavy chain of IMMUNOGLOBULIN G or IMMUNOGLOBULIN M). The interaction of C1q and immunoglobulin activates the two proenzymes COMPLEMENT C1R and COMPLEMENT C1S, thus initiating the cascade of COMPLEMENT ACTIVATION via the CLASSICAL COMPLEMENT PATHWAY.
Also Known As:
C1q Complement; Complement 1q; Complement Component 1q; C1q, Complement; Complement, C1q; Component 1q, Complement
Networked: 221
relevant articles (3 outcomes,
22 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Experts
1. | Trendelenburg, Marten:
9 articles
(01/2021 - 11/2005)
|
2. | Severance, Emily G:
4 articles
(11/2016 - 12/2012)
|
3. | Yolken, Robert H:
4 articles
(11/2016 - 12/2012)
|
4. | Sumbul, Hilmi Erdem:
3 articles
(01/2022 - 12/2020)
|
5. | Wang, Qin:
3 articles
(01/2022 - 10/2020)
|
6. | Gressitt, Kristin L:
3 articles
(11/2016 - 12/2012)
|
7. | Lu, Jinhua:
3 articles
(09/2015 - 08/2010)
|
8. | Bigler, Cornelia:
3 articles
(04/2011 - 09/2009)
|
9. | Danner, Doris:
3 articles
(04/2011 - 09/2008)
|
10. | Schaller, Monica:
3 articles
(04/2011 - 09/2009)
|
Related Diseases
1. | Atherosclerosis
|
2. | Cognitive Dysfunction
01/01/2021
- " Microglia-selective genetic deletion of CNS complement C1q ameliorates radiation-induced cognitive impairments, synaptic loss, and neuroinflammation, highlighting the potential for C1q as a novel therapeutic target.See" 10/01/2023
- " Complement C1q drives microglia-dependent synaptic loss and cognitive impairments in a mouse model of lipopolysaccharide-induced neuroinflammation." 02/17/2020
- " The study evaluated levels of both CHI3L1 and CHI3L2, NPTX2, ionized calcium-binding adapter molecule 1 (Iba1), complement component 1q (C1q), glial fibrillary acidic protein (GFAP), and CD44, in the frontal cortex of people who died with an antemortem clinical diagnosis of no cognitive impairment (NCI), mild cognitive impairment (MCI), mild/moderate AD (mAD), and severe AD (sAD) using immunoblot and immunohistochemical techniques. "
|
3. | Lung Neoplasms (Lung Cancer)
|
4. | Neuroinflammatory Diseases
|
5. | Type 2 Diabetes Mellitus (MODY)
|
|
Related Drugs and Biologics
Related Therapies and Procedures